Effect of Cilostazol Prescribed in a Pragmatic Treatment Program for Intermittent Claudication

Lee, Constance; Nelson, Peter R.

doi:10.1177/1538574413518121

Cited by 28 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…119 However, side effects include headache, diarrhea, dizziness, and palpitations and in 1 trial, 20% of patients discontinued cilostazol within 3 months. 120 …”

Section: Medical Therapy For the Patient With Pad: Recommendationsmentioning

confidence: 99%

2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

et al. 2017

View full text Add to dashboard Cite

Preamble Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, based on systematic methods to evaluate and classify evidence, provide a cornerstone of quality cardiovascular care. In response to reports from the Institute of Medicine1,2 and a mandate to evaluate new knowledge and maintain relevance at the point of care, the ACC/AHA Task Force on Clinical Practice Guidelines (Task Force) modified its methodology.3–5 The relationships among guidelines, data standards, appropriate use criteria, and performance measures are addressed elsewhere.5 Intended Use Practice guidelines provide recommendations applicable to patients with or at risk of developing cardiovascular disease. The focus is on medical practice in the United States, but guidelines developed in collaboration with other organizations may have a broader target. Although guidelines may be used to inform regulatory or payer decisions, the intent is to improve quality of care and align with patients' interests. Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances, and should not replace clinical judgment. Guidelines are reviewed annually by the Task Force and are official policy of the ACC and AHA. Each guideline is considered current until it is updated, revised, or superseded by published addenda, statements of clarification, focused updates, or revised full-text guidelines. To ensure that guidelines remain current, new data are reviewed biannually to determine whether recommendations should be modified. In general, full revisions are posted in 5-year cycles.3–6 Modernization Processes have evolved to support the evolution of guidelines as “living documents” that can be dynamically updated. This process delineates a recommendation to address a specific clinical question, followed by concise text (ideally <250 words) and hyperlinked to supportive evidence. This approach accommodates time constraints on busy clinicians and facilitates easier access to recommendations via electronic search engines and other evolving technology. Evidence Review Writing committee members review the literature; weigh the quality of evidence for or against particular tests, treatments, or procedures; and estimate expected health outcomes. In developing recommendations, the writing committee uses evidence-based methodologies that are based on all available data.3–7 Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only selected references are cited. The Task Force recognizes the need for objective, independent Evidence Review Committees (ERCs) that include methodologists, epidemiologists, clinicians, and biostatisticians who systematically survey, abstract, and assess the evidence t...

show abstract

“…119 However, side effects include headache, diarrhea, dizziness, and palpitations and in 1 trial, 20% of patients discontinued cilostazol within 3 months. 120 …”

Section: Medical Therapy For the Patient With Pad: Recommendationsmentioning

confidence: 99%

2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Its effects are believed to be mediated by its vasodilatory properties as well as an inhibitory effect on platelet aggregation. 3,4 In addition, newer studies suggest cilostazol may play a role in decreasing intimal hyperplasia after angioplasty and stenting in coronary vessels. [5][6][7] In patients with PAD undergoing a lower extremity revascularization (LER) procedure, the goal of therapy is to prevent limb loss.…”

mentioning

confidence: 99%

Cilostazol and freedom from amputation after lower extremity revascularization

Neel

Kruse

Dombrovskiy

et al. 2015

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

“…Cilostazol is an effective medical therapy for treatment of leg symptoms and walking impairment due to claudication (119). However, side effects include headache, diarrhea, dizziness, and palpitations and in 1 trial, 20% of patients discontinued cilostazol within 3 months (120). See Online Data Supplements 13 to 19 for data supporting Section 5.…”

Section: Medical Therapy For the Patient With Pad: Recommendationsmentioning

confidence: 99%

2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary

Gerhard‐Herman¹,

Gornik²,

Barrett³

et al. 2017

Vasc Med

183

View full text Add to dashboard Cite

Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information. 2 Functioning as the lay volunteer/ patient representative. 3 ACC/AHA Representative. 4 Vascular and Endovascular Surgery Society Representative. 5 Society for Cardiovascular Angiography and Interventions Representative. 6 ACC/AHA Task Force on Clinical Practice Guidelines Liaison. 7 Inter-Society Consensus for the Management of Peripheral Arterial Disease Representative. 8 Society for Vascular Medicine Representative; 9 Society of Interventional Radiology Representative. 10 Society for Clinical Vascular Surgery Representative. 11 Society for Vascular Surgery Representative.

show abstract

Effect of Cilostazol Prescribed in a Pragmatic Treatment Program for Intermittent Claudication

Abstract: Despite minimal behavior modification, up to 70% of patients taking cilostazol report an improvement in claudication symptoms with few side effects.

Cited by 28 publications

References 29 publications

2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Cilostazol and freedom from amputation after lower extremity revascularization

2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary

Contact Info

Product

Resources

About